Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 33.3 Million SEK | -38.84% |
| 2022 | 54.45 Million SEK | 54.57% |
| 2021 | 35.23 Million SEK | -22.57% |
| 2020 | 45.49 Million SEK | 19.28% |
| 2019 | 38.14 Million SEK | 2.43% |
| 2018 | 37.23 Million SEK | 36.52% |
| 2017 | 27.27 Million SEK | -19.55% |
| 2016 | 33.9 Million SEK | -1.26% |
| 2015 | 34.33 Million SEK | -8.4% |
| 2014 | 37.48 Million SEK | -35.77% |
| 2013 | 58.35 Million SEK | 31.57% |
| 2012 | 44.35 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 28.28 Million SEK | 3.81% |
| 2024 Q1 | 42.69 Million SEK | 28.21% |
| 2024 Q2 | 27.24 Million SEK | -36.2% |
| 2023 Q3 | 50.14 Million SEK | 9.62% |
| 2023 FY | 33.3 Million SEK | -38.84% |
| 2023 Q2 | 45.74 Million SEK | -9.23% |
| 2023 Q1 | 50.39 Million SEK | -7.46% |
| 2023 Q4 | 33.3 Million SEK | -33.58% |
| 2022 Q4 | 54.45 Million SEK | 12.14% |
| 2022 Q3 | 48.56 Million SEK | 9.82% |
| 2022 FY | 54.45 Million SEK | 54.57% |
| 2022 Q1 | 39.45 Million SEK | 12.0% |
| 2022 Q2 | 44.22 Million SEK | 12.07% |
| 2021 Q4 | 35.23 Million SEK | -9.73% |
| 2021 Q1 | 44.91 Million SEK | -1.29% |
| 2021 Q2 | 42.8 Million SEK | -4.69% |
| 2021 Q3 | 39.02 Million SEK | -8.83% |
| 2021 FY | 35.23 Million SEK | -22.57% |
| 2020 FY | 45.49 Million SEK | 19.28% |
| 2020 Q4 | 45.49 Million SEK | 17.64% |
| 2020 Q3 | 38.67 Million SEK | 16.49% |
| 2020 Q1 | 48.06 Million SEK | 26.0% |
| 2020 Q2 | 33.2 Million SEK | -30.92% |
| 2019 Q4 | 38.14 Million SEK | -5.12% |
| 2019 Q1 | 34.37 Million SEK | -7.68% |
| 2019 FY | 38.14 Million SEK | 2.43% |
| 2019 Q3 | 40.2 Million SEK | -3.25% |
| 2019 Q2 | 41.55 Million SEK | 20.87% |
| 2018 Q2 | 33.77 Million SEK | -5.54% |
| 2018 Q3 | 39.12 Million SEK | 15.85% |
| 2018 Q4 | 37.23 Million SEK | -4.83% |
| 2018 FY | 37.23 Million SEK | 36.52% |
| 2018 Q1 | 35.75 Million SEK | 31.08% |
| 2017 Q4 | 27.27 Million SEK | -0.81% |
| 2017 FY | 27.27 Million SEK | -19.55% |
| 2017 Q3 | 27.5 Million SEK | -1.94% |
| 2017 Q2 | 28.04 Million SEK | -15.54% |
| 2017 Q1 | 33.2 Million SEK | -2.07% |
| 2016 Q2 | 38.72 Million SEK | 17.6% |
| 2016 Q4 | 33.9 Million SEK | -20.0% |
| 2016 FY | 33.9 Million SEK | -1.26% |
| 2016 Q1 | 32.93 Million SEK | -4.09% |
| 2016 Q3 | 42.38 Million SEK | 9.43% |
| 2015 Q1 | 43.32 Million SEK | 15.58% |
| 2015 FY | 34.33 Million SEK | -8.4% |
| 2015 Q4 | 34.33 Million SEK | -34.45% |
| 2015 Q3 | 52.38 Million SEK | 34.73% |
| 2015 Q2 | 38.87 Million SEK | -10.25% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | 75.3 Million SEK | 0.0% |
| 2014 Q4 | 37.48 Million SEK | -50.23% |
| 2014 FY | 37.48 Million SEK | -35.77% |
| 2013 Q4 | 58.35 Million SEK | 0.0% |
| 2013 FY | 58.35 Million SEK | 31.57% |
| 2012 FY | 44.35 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -202.828% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.755% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.755% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 89.898% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.98% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 88.101% |
| CellaVision AB (publ) | 212.32 Million SEK | 84.314% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -134.592% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -384.864% |
| C-Rad AB (publ) | 122.4 Million SEK | 72.79% |
| Duearity AB (publ) | 17.53 Million SEK | -89.989% |
| Dignitana AB (publ) | 37.56 Million SEK | 11.345% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -68.207% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.865% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -61.672% |
| Iconovo AB (publ) | 14.55 Million SEK | -128.839% |
| Integrum AB (publ) | 22.07 Million SEK | -50.887% |
| Luxbright AB (publ) | 7 Million SEK | -375.778% |
| Mentice AB (publ) | 163.55 Million SEK | 79.637% |
| OssDsign AB (publ) | 105.25 Million SEK | 68.358% |
| Paxman AB (publ) | 44.5 Million SEK | 25.172% |
| Promimic AB (publ) | 16.15 Million SEK | -106.146% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 46.428% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -56.523% |
| ScandiDos AB (publ) | 37.18 Million SEK | 10.437% |
| Sectra AB (publ) | 1.64 Billion SEK | 97.971% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 24.413% |
| Senzime AB (publ) | 58.06 Million SEK | 42.642% |
| SpectraCure AB (publ) | 14.97 Million SEK | -122.404% |
| Stille AB | 172.64 Million SEK | 80.708% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.092% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 86.708% |